Débora Barton

Carisma Therapeutics (United States) — United States

Medicine · Health Sciences

10h-index712citations47works22.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(29), Monoclonal and Polyclonal Antibodies Research(12), Immune cells in cancer(10), Cancer Treatment and Pharmacology(7), Phagocytosis and Immune Regulation(7)

Publications47 total

CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
Nature Medicine·2025· 127 cited
A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.
Journal of Clinical Oncology·2024· 1 cited
Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors.
Journal of Clinical Oncology·2024· 2 cited
Abstract CT170: Trial in progress: A phase 1, first in human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors
Cancer Research·2024
Abstract CT151: Trial in progress:A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation
Cancer Research·2024
TSC-100 and TSC-101, TCR-T Cell Therapies That Target Residual Recipient Cells after Reduced Intensity Conditioning Transplantation, Induce Complete Donor Chimerism with Favorable Prognosis: Early Results of a Phase 1 Trial
Transplantation and Cellular Therapy·2024· 5 cited
Initial Results of a Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation
Blood·2023· 4 cited
376 Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cell therapy in Phase 1
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
682 Trial in progress: phase 1 trial of TSC-100 and TSC-101, engineered T-cell therapies targeting minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation
Regular and Young Investigator Award Abstracts·2023Open Access
709 Trial in progress: product characteristics and clinical trial design for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy for solid tumors
Regular and Young Investigator Award Abstracts·2023Open Access
635 A phase 1, first in human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2023· 1 citedOpen Access
A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.
Journal of Clinical Oncology·2023· 13 cited
Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor engineered T cell therapy for solid tumors.
Journal of Clinical Oncology·2023
Abstract CT241: A phase 1, first-in-human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophage (CAR-M) in participants (pt) with HER2 overexpressing solid tumors
Cancer Research·2023· 2 cited
Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation
Blood·2022· 1 cited
634 A phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2022· 8 citedOpen Access
633 A phase 1, first in human (FIH) study of autologous macrophages containing an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors
Regular and Young Investigator Award Abstracts·2022· 6 citedOpen Access
Abstract CT524: A phase 1, first in human (FIH) study of autologous anti-HER2 chimeric antigen receptor macrophages (CAR-M) in HER2-overexpressing solid tumors (ST)
Cancer Research·2022
A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors.
Journal of Clinical Oncology·2022· 42 cited
A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.
Journal of Clinical Oncology·2022· 2 cited
page 1 of 3Next →

Frequent Co-authors

Michael Klichinsky(16), Amy Ronczka(15), Daniel Cushing(15), Yuan Yuan(11), Gavin MacBeath(11), Shrikanta Chattopadhyay(11), Thomas Condamine(10), Yara Abdou(10), Kim A. Reiss(9), Naoto T. Ueno(9), Ramona F. Swaby(9), Saar Gill(9), Mathew G. Angelos(8), Elizabeth Claire Dees(8), J. A. H. Murray(8), Denise A. Yardley(7), Pierfranco Conté(7), Javier Cortés(7), Adam Brufsky(7), Nadia Harbeck(7)